OpusPoint Partners: Taking Brave Steps towards Better Healthcare and Medical Services
Dr. Lindsay Rosenwald and OpusPoint Partners, together with colleagues and companies who share their mission to advance life sciences and biotechnology, are taking big and daring steps to provide superior healthcare and medical services to people afflicted with diseases. By investing their time, money and knowledge to support small, promising companies, which aim to develop drugs vital to treatment or effective management of serious illnesses, they offer eternal hope to patients and to the world in general.
OpusPoint Partners facilitates and coordinates drug research and corporate projects for their portfolio companies. OpusPoint is a development and investment company that specializes in the creation, assistance and financial support for new and potential-laden biotechnology companies. This company is the creation of Michael S. Weiss and Dr. Lindsay Rosenwald. They bring in more than 40 years of collective experience in life sciences and biotechnology investing. These financial gurus started the business enterprise in 2009 with the focus on bankrolling biotechnological research and developments.
Dr. Lindsay Rosenwald and OpusPoint Partners are fully aware of the fact that financing is critical to the achievement of crucial goals. Small and start-up companies often have limited funding and limitless potentials. They need a sufficient amount of financial support and expert counsel to help them realize their objectives, and OpusPoint Partners provide them exactly those things.
OpusPoint Partners, being an investment firm is driven by capital margins and investment returns. But what separate OpusPoint from the rest is their fair, honest and transparent transaction, most especially in the management of experimental drug trials, analysis and drug manufacturing. Dr. Lindsay Rosenwald and his partners believe that profitable business is highly viable even when you follow stringent business rules and obey morally upright practices. They are fully convinced that they do not need to manipulate clinical trials to make big profits in a short period of time.
In reality, OpusPoint Partners have accomplished so much in drug research in just two years. They have now gone above income projections and have reaped exceptional returns. In such a short time, OpusPoint is already funding and guiding more than 20 value-infused companies, which guarantee more capital gains.